Mycophenolate mofetil and atherosclerosis: Results of animal and human studies

Annals of the New York Academy of Sciences

Volumn 1110, Issue , 2007, Pages 209-221

  Gibson, William Thomas ^a   Hayden, Michael Reuben ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atherosclerosis; Coronary allograft vasculopathy; Immunosuppressants; Mycophenolate mofetil; Mycophenolic acid; Transplantation

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CORTISONE; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SIMVASTATIN; TACROLIMUS;

ATHEROSCLEROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG INHIBITION; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; MORTALITY; NONHUMAN; PREVENTION AND CONTROL; RISK FACTOR;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 35748963843     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1423.023     Document Type: Conference Paper

References (50)

1. HANSSON, G.K., A.L. ROBERTSON & C. SODERBERG-NAUCLER. 2006. Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis. 1: 297-329.
2. ALLISON, A.C., W.J. KOWALSKI, C.J. MULLER, et al. 1993. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc. 25: 67-70.
3. BARTEN, M.J., T. VAN GELDER, J.F. GUMMERT, et al. 2002. Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection. Am. J. Transplant. 2: 719-732.
4. LAURENT, A.F., S. DUMONT, P. POINDRON, et al. 1996. Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp. Hematol. 24: 59-67.
5. BLAHETA, R.A., K. LECKEL, B. WITTIG, et al. 1998. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil. Transpl. Immunol. 6: 251-259.
6. VALENTIN, J.F., J.A. BRUIJN & L.C. PAUL. 2000. Donor treatment with mycophenolate mofetil: protection against ischemia-reperfusion injury in the rat. Transplantation 69: 344-350.
7. ALLISON, A.C. & E.M. EUGUI. 1993. The design and development of an immunosuppressive drug, mycophenolate mofetil. Springer Semin. Immunopathol. 14: 353-380.
8. SHIMIZU, H., M. TAKAHASHI, S. TAKEDA, et al. 2004. Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation. Transplantation 77: 1661-1667.
9. SCHWARZE, M.L., S.L. HOUSER, A. MUNIAPPAN, et al. 2005. Effects of mycophenolate mofetil on cardiac allograft survival and cardiac allograft vasculopathy in miniature swine. Ann. Thorac. Surg. 80: 1787-1793.
10. ALLISON, A.C. & E.M. EUGUI. 2005. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80: S181-S190.
11. NAGY, S.E., J.P. ANDERSSON & U.G. ANDERSSON. 1993. Effect of mycophenolate mofetil (RS-61443) on cytokine production: inhibition of superantigen-induced cytokines. Immunopharmacology 26: 11-20.
12. IZERADJENE, K., L. QUEMENEUR, M.C. MICHALLET, et al. 2001. Mycophenolate mofetil interferes with interferon gamma production in T-cell activation models. Transplant Proc. 33: 2110-2111.
13. IZERADJENE, K. & J.P. REVILLARD. 2001. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation 71: 118-125.
14. LUI, S.L., V. RAMASSAR, J. URMSON, et al. 1998. Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion. Transpl. Immunol. 6: 23-32.
15. VAN LEUVEN, S.I., J.J. KASTELEIN, M.R. HAYDEN, et al. 2005. Cardiovascular disease in systemic lupus erythematosus: has the time for action come? Curr. Opin. Lipidol. 16: 501-506.
16. ROMAN, M.J., B.A. SHANKER, A. DAVIS, et al. 2003. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2399-2406.
17. ASANUMA, Y., A. OESER, A.K. SHINTANI, et al. 2003. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349: 2407-2415.
18. MANZI, S., E.N. MEILAHN, J.E. RAIRIE, et al. 1997. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145: 408-415.
19. WAJED, J., Y. AHMAD, P.N. DURRINGTON, et al. 2004. Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology (Oxf.) 43: 7-12.
20. GAZARIAN, M., B.M. FELDMAN, L.N. BENSON, et al. 1998. Assessment of myocardial perfusion and function in childhood systemic lupus erythematosus. J. Pediatr. 132: 109-116.
21. GUEVARA, J.P., B.J. CLARK & B.H. ATHREYA. 2001. Point prevalence of cardiac abnormalities in children with systemic lupus erythematosus. J. Rheumatol. 28: 854-859.
22. ALLISON, A.C. 2004. Two lessons from the interface of genetics and medicine. Genetics 166: 1591-1599.
23. GIBLETT, E.R., J.E. ANDERSON, F. COHEN, et al. 1972. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2: 1067-1069.
24. GOSIO, B. 1896. Ricerche batteriologiche e chimich sulle alterazioni del mais. Rivista Igiene Sanita Pubblica Ann 7: 825-868.
25. CARR, S.F., E. PAPP, J.C. WU, et al. 1993. Characterization of human type I and type II IMP dehydrogenases. J. Biol. Chem. 268: 27286-27290.
26. ALLISON, A.C., S.J. ALMQUIST, C.D. MULLER, et al. 1991. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc. 23: 10-14.
27. RICHTER, M.H., S. ZAHN, M. KRAUS, et al. 2003. Mycophenolate mofetil significantly reduces leukocyte graft infiltration after heterotopic cardiac transplantation in a rat model: comparative study with cyclosporine and FK 506. J. Heart Lung Transplant 22: 1107-1116.
28. RICHTER, M., S. ZAHN, H. RICHTER, et al. 2004. Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy. J. Heart Lung Transplant 23: 1405-1413.
29. RAISANEN-SOKOLOWSKI, A., P. VUORISTO, M. MYLLARNIEMI, et al. 1995. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl. Immunol. 3: 342-351.
30. SHIMIZU, H., M. TAKAHASHI, S. TAKEDA, et al. 2004. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts. Transpl. Immunol. 13: 219-227.
31. FRASER-SMITH, E.B., J.D. ROSETE & R.C. SCHATZMAN. 1995. Suppression by mycophenolate mofetil of the neointimal thickening caused by vascular injury in a rat arterial stenosis model. J. Pharmacol. Exp. Ther. 275: 1204-1208.
32. O'HAIR, D.P., R.P. MCMANUS & R. KOMOROWSKI. 1994. Inhibition of chronic vascular rejection in primate cardiac xenografts using mycophenolate mofetil. Ann. Thorac. Surg. 58: 1311-1315.
33. KLUPP, J., C. DAMBRIN, K. HIBI, et al. 2003. Treatment by mycophenolate mofetil of advanced graft vascular disease in non-human primate recipients of orthotopic aortic allografts. Am. J. Transplant. 3: 817-829.
34. SCHREIBER, T.C., S.M. GREENSTEIN, D.Y. KIM, et al. 1998. Effect ofmycophenolate mofetil on atherosclerosis in a rabbit model: initial histologic and immunohistochemical analyses. Transplant Proc. 30: 961-962.
35. GREENSTEIN, S.M., S. SUN, T.M. CALDERON, et al. 2000. Mycophenolate mofetil treatment reduces atherosclerosis in the cholesterol-fed rabbit. J. Surg. Res. 91: 123-129.
36. ROMERO, F., B. RODRIGUEZ-ITURBE, H. PONS, et al. 2000. Mycophenolate mofetil treatment reduces cholesterol-induced atherosclerosis in the rabbit. Atherosclerosis 152: 127-133.
37. KOBASHIGAWA, J., L. MILLER, D. RENLUND, et al. 1998. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 66: 507-515.
38. EISEN, H.J., J. KOBASHIGAWA, A. KEOGH, et al. 2005. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J. Heart Lung Transplant. 24: 517-525.
39. KOBASHIGAWA, J.A. 2006. Cardiac allograft vasculopathy in heart transplant patients: pathologic and clinical aspects for angioplasty/stenting. J. Am. Coll. Cardiol. 48: 462-463.
40. LI, H., K. TANAKA, A. CHHABRA, et al. 2007. Vascular remodeling 1 year after cardiac transplantation. J. Heart Lung Transplant. 26: 56-62.
41. KOBASHIGAWA, J.A., J.M. TOBIS, R.M. MENTZER, et al. 2006. Mycophenolate mofetil reduces intimal thickness by intravascular ultrasound after heart transplant: reanalysis of the multicenter trial. Am. J. Transplant. 6: 993-997.
42. WEIS, M., S.M. WILDHIRT, C. SCHULZE, et al. 2000. Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens. J. Cardiovasc. Pharmacol. 36: 776-784.
43. PETHIG, K., B. HEUBLEIN, T. WAHLERS, et al. 2004. Mycophenolate mofetil for secondary prevention of cardiac allograft vasculopathy: influence on inflammation and progression of intimal hyperplasia. J. Heart Lung Transplant. 23: 61-66.
44. HOSENPUD, J.D. & L.E. BENNETT. 2001. Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry. Transplantation 72: 1662-1665.
45. FUCHS, U., G. TENDERICH, A. ZITTERMANN, et al. 2006. Clinical outcome of heart transplant recipients receiving tacrolimus with or without mycophenolate mofetil. Clin. Transplant. 20: 450-456.
46. EL-SAYED, O., R.D. MAGORIEN, A. ORSINI, et al. 2005. Advancing immunosuppression therapy to counter the progression of cardiac allograft vasculopathy. J. Card. Fail. 11: 137-141.
47. KACZMAREK, I., B. ERTL, D. SCHMAUSS, et al. 2006. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J. Heart Lung Transplant. 25: 550-556.
48. DAVID, K.M., J.A. MORRIS, B.J. STEFFEN, et al. 2005. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin. Transplant. 19: 279-285.
49. WEIGEL, G., A. GRIESMACHER, A. KARIMI, et al. 2002. Effect of mycophenolate mofetil therapy on lymphocyte activation in heart transplant recipients. J. Heart Lung Transplant. 21: 1074-1079.
50. VAN LEUVEN, S.I., J.J. KASTELEIN, A.C. ALLISON, et al. 2006. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc. Res. 69: 341-347.